Total Synthetic Development and Pharmacological Screening of Bioactive Isolated from Syzygium cuminii (l) Skeel

June 24, 2020

Title

Total Synthetic Development and Pharmacological Screening of Bioactive Isolated from Syzygium cuminii (l) Skeel

Author

Nikhat Farhana

Year

2020

Journal

Biointerface Research in Applied Chemistry, Research Articale Volume 10, Issue 5, 2020, 6550 - 6564

Abstract

Syzygium cumini (L.) Skeels (or Eugenia jambolana) is a species that belongs to the Myrtaceae family been used empirically to treat various diseases, one of them is antidiabetic. The study reported the phytochemical analysis and pharmacological screening of In-vivo, antidiabetic test conducted on bioactive (separated by column isolation method from aqueous extract) in streptozotocine induced diabetes rat modelling at dose level of 50 g/kg BW, on the basis of TLC and spectral analysis of activity guided bioactive will be chemically designate as 4-(2-amino-2 -(2-(2-hydroxy-3-methyl butyl) octahydropyrrolo-[1,2-a] pyrazin-7-yl)-ethyl)-2- ethylpheno (ScReX-2), Total synthetic methodology accomplished using key BoC protected, pyrazine and methyl amine followed by condensation with application of simple Diels-alder reaction of fragment by cyclization. The Structure elucidation of the newly synthesized ScReX-2 was performed by means of FT-IR, 1H-NMR, 13C-NMR, the antidiabetic activity showed that the effect of synthesized molecule at dose level of 50mg/kg BW was exhibits more potent significantly then glibenclamide to reduce the blood glucose levels subset of the statistics ANOVA (p> 0.05). The study concludes that the synthesized bioactive is having potent antidiabetic activity then compared with isolated molecule as well as glibenclamide

Instrument

V-550 UV/Vis spectrometer, P-2000 polarimeter

Keywords

Syzygium cumiini L skeel; myretaceae; bioactive; total synthesis; antidiabetic; glibenclamide